Cobolimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Cobolimab Usage And Synthesis

Uses

Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC)[1][2][3].

References

[1] Falchook G S, et al. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER)[J]. 2022.
[2] Markham A. Dostarlimab: First Approval. Drugs. 2021 Jul;81(10):1213-1219. DOI:10.1007/s40265-021-01539-5
[3] Kuang Z, et al. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy. Antib Ther. 2020 Nov 9;3(4):227-236. DOI:10.1093/abt/tbaa022
[4] Sun CY, et al. T cell exhaustion drives osteosarcoma pathogenesis. Ann Transl Med. 2021 Sep;9(18):1447. DOI:10.21037/atm-21-3928

Cobolimab(2022215-65-0)Related Product Information

• Tinurilimab
• Vedolizumab
• Ibalizumab
• Meplazumab
• Enfortumab Vedotin
• Lirilumab
• bimekizumab
• Tamrintamab
• Fresolimumab
• Tigatuzumab